AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39438096 — intervention group
Group type: COMPARATOR
Intervention: Placebo on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Number of subjects: 49
Study 39438099 — intervention group
Group type: EXPERIMENTAL
Intervention: END-IT NH 6-component intervention
Number of subjects: 60
Study 39438099 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 39438108 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuming DOAC at standard dosing starting at 30 days (30+7)
Number of subjects: 0
Study 39438108 — intervention group
Group type: COMPARATOR
Intervention: Resuming DOAC at standard dosing starting at 90 days (90±14)
Number of subjects: 0
Study 39438108 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 39438105 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group-based walking intervention
Number of subjects: 184
Study 39438105 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised group-based walking intervention
Number of subjects: 184
Study 39438105 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised individual-based walking intervention
Number of subjects: 184
Study 39438105 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 39438104 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness intervention
Number of subjects: 30
Study 39438104 — intervention group
Group type: COMPARATOR
Intervention: Sham VR control (relaxing nature videos)
Number of subjects: 30
Study 39438126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg daily for 10 days
Number of subjects: 124
Study 39438126 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine 20 mg three times per day for 10 days
Number of subjects: 124
Study 39438203 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated severe obstructive sleep apnea (OSA) (AHI≥30 events/h)
Number of subjects: 58
Study 39438203 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA (AHI<15 events/h)
Number of subjects: 58
Study 39438214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 27
Study 39438236 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Enhanced Depression Care
Number of subjects: 149
Study 39438236 — intervention group
Group type: COMPARATOR
Intervention: Nonpeer, social interaction control
Number of subjects: 149
Study 39438322 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 117
Study 39438322 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 117
Study 39438442 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 (aPD1) plus chemoradiotherapy (CRT)
Number of subjects: 24
Study 39438442 — intervention group
Group type: EXPERIMENTAL
Intervention: aPD1-CRT
Number of subjects: 24
Study 39438467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg/day) combined with methylprednisolone (1 mg/kg/day)
Number of subjects: 198
Study 39438467 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone (2 mg/kg/day)
Number of subjects: 198
Study 39438591 — intervention group
Group type: EXPERIMENTAL
Intervention: Xacrel
Number of subjects: 170
Study 39438591 — intervention group
Group type: COMPARATOR
Intervention: Ocrevus
Number of subjects: 170
Study 39438621 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) ML model in internal validation cohort
Number of subjects: 10874
Study 39438621 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) ML model in temporal validation cohort
Number of subjects: 10874
Study 39438797 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers and facilitators to social connection identified through thematic analysis.
Number of subjects: 67
Study 39438885 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person peer support groups
Number of subjects: 500
Study 39438885 — intervention group
Group type: COMPARATOR
Intervention: WhatsApp-facilitated mobile groups
Number of subjects: 500
Study 39438915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapt 2 Asthma (A2A)
Number of subjects: 280
Study 39438915 — intervention group
Group type: COMPARATOR
Intervention: Asthma self-management control arm (APK)
Number of subjects: 280
Study 39438920 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities 2.0 (SHHC-2.0) intervention
Number of subjects: 11
Study 39438920 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 11
Study 39438942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 mg once daily)
Number of subjects: 102
Study 39438942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 39439007 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml/kg Ringer's Lactate infusion over 10 min
Number of subjects: 40
Study 39439041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid telemental health (TMH) treatment
Number of subjects: 0
Study 39439041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid TMH treatment
Number of subjects: 0
Study 39439041 — intervention group
Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 0
Study 39439294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13194
Study 39439294 — intervention group
Group type: COMPARATOR
Intervention: Enalapril or valsartan
Number of subjects: 13194
Study 39439530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus aspirin
Number of subjects: 9049
Study 39439530 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 9049
Study 39439726 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mobile chat messaging support for relapse prevention, including cessation advice from a live counselor and access to a supportive chatbot via WhatsApp for 3 months
Number of subjects: 586
Study 39439726 — intervention group
Group type: COMPARATOR
Intervention: Text messaging on generic cessation advice for 3 months as attention control
Number of subjects: 586
Study 39439726 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mobile chat messaging support for relapse prevention
Number of subjects: 586
Study 39439755 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-based behavioral activation (VBA)
Number of subjects: 21
Study 39440042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified trans-sectoral nutritional intervention for 6 months (face-to-face dietary counseling, oral nutritional supplementation, telephone-based nutrition and exercise coaching)
Number of subjects: 9
Study 39440409 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg oral solution of misoprostol
Number of subjects: 874
Study 39440409 — intervention group
Group type: COMPARATOR
Intervention: 25 μg oral tablet of misoprostol
Number of subjects: 874
Study 39440428 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle-optimized therapy CRT (LOT-CRT)
Number of subjects: 48
Study 39440428 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BVP)
Number of subjects: 48
Study 39440428 — intervention group
Group type: COMPARATOR
Intervention: Left bundle branch area pacing (LBBAP)
Number of subjects: 48
Study 39440720 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE items
Number of subjects: 899
Study 39440720 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE administration and reporting recommendations
Number of subjects: 899
Study 39440742 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with remote monitoring
Number of subjects: 335
Study 39441133 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention through interactive voice-response (PDI-IVR) system
Number of subjects: 263
Study 39441133 — intervention group
Group type: COMPARATOR
Intervention: Active-control
Number of subjects: 263
Study 39441230 — intervention group
Group type: EXPERIMENTAL
Intervention: High iodine levels in cooking water
Number of subjects: 770
Study 39441230 — intervention group
Group type: EXPERIMENTAL
Intervention: High iodine levels in drinking water
Number of subjects: 770
Study 39441230 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary iodine concentration (UIC)
Number of subjects: 770
Study 39441230 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 24-h urinary iodine excretion (24-h UIE)
Number of subjects: 770
Study 39441346 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 768
Study 39441346 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 768
Study 39441346 — intervention group
Group type: COMPARATOR
Intervention: No mechanical ventilation (NV)
Number of subjects: 768
Study 39441483 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) 4 × 8 Gy and sequential nivolumab administration until disease progression or unacceptable toxicity
Number of subjects: 15
Study 39441483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 15
Study 39441483 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) analysis
Number of subjects: 15
Study 39441503 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game condition
Number of subjects: 39
Study 39441503 — intervention group
Group type: COMPARATOR
Intervention: Control game
Number of subjects: 39
Study 39441519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 10-200/50 mg
Number of subjects: 718
Study 39441519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 39441519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (all doses)
Number of subjects: 718
Study 39441519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (SALT score ≤ 20 responders)
Number of subjects: 718
Study 39441519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 718
Study 39441580 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 542
Study 39441580 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 542
Study 39441580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 39441591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (50-300 mg/d)
Number of subjects: 10
Study 39441591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 39441642 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioral therapy (bCBT) combining internet-based cognitive behavioral therapy (iCBT) and face-to-face cognitive behavioral therapy (FtF CBT)
Number of subjects: 13
Study 39441642 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (FtF CBT)
Number of subjects: 13
Study 39441642 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 13
Study 39441691 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938
Number of subjects: 124
Study 39441691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 39441802 — intervention group
Group type: EXPERIMENTAL
Intervention: hf-tRNS
Number of subjects: 45
Study 39441802 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz tACS
Number of subjects: 45
Study 39441802 — intervention group
Group type: COMPARATOR
Intervention: sham tCS
Number of subjects: 45
Study 39441802 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 39441873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary rehabilitation program (30 sessions over 6 weeks)
Number of subjects: 72
Study 39441873 — intervention group
Group type: COMPARATOR
Intervention: Home-based self-treatment program (muscle-stretching and active mobilization exercises for 40'/day for 6 weeks)
Number of subjects: 72
Study 39441901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 0
Study 39442013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W or Q4W combined with topical corticosteroids (TCS) in the maintenance primary population (MPP)
Number of subjects: 271
Study 39442013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W with TCS in the maintenance escape population (MEP)
Number of subjects: 271
Study 39442013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W or Q4W combined with TCS in the MPP
Number of subjects: 271
Study 39442013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W with TCS in the MEP
Number of subjects: 271
Study 39442018 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 654
Number of subjects: 0
Study 39442018 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab RP
Number of subjects: 0
Study 39442018 — intervention group
Group type: COMPARATOR
Intervention: Transition from Ustekinumab RP to ABP 654 at week 28
Number of subjects: 0
Study 39442326 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (diaphragmatic plication)
Number of subjects: 139
Study 39442326 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (clinical follow-up)
Number of subjects: 139
Study 39442386 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Jaktinib administered orally on day 1 in mild hepatic impairment group (n=8)
Number of subjects: 24
Study 39442386 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Jaktinib administered orally on day 1 in moderate hepatic impairment group (n=8)
Number of subjects: 24
Study 39442386 — intervention group
Group type: COMPARATOR
Intervention: 100 mg Jaktinib administered orally on day 1 in normal hepatic function group (n=8)
Number of subjects: 24
Study 39442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Caries Removal (TCR)
Number of subjects: 124
Study 39442480 — intervention group
Group type: COMPARATOR
Intervention: Selective Caries Removal (SCR)
Number of subjects: 124
Study 39442667 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND (Motivational Interviewing-Enhanced Behavior Therapy)
Number of subjects: 278
Study 39442667 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 278
Study 39442695 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention including supplementary mental health training for nurses, workshops for doctors, and lay counselling services.
Number of subjects: 4298
Study 39442757 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals (3 test meals)
Number of subjects: 42
Study 39442757 — intervention group
Group type: EXPERIMENTAL
Intervention: PLS regression model with 16 SNPs
Number of subjects: 42
Study 39442905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative molecular imaging (IMI) with pafolacianine
Number of subjects: 100
Study 39442958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive adjuvant treatment (arm A): four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (n=166)
Number of subjects: 504
Study 39442958 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (arm B): four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (n=170)
Number of subjects: 504
Study 39442958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive adjuvant treatment (arm A)
Number of subjects: 504
Study 39442958 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (arm B)
Number of subjects: 504
Study 39443013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (FDI)
Number of subjects: 1137
Study 39443013 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1137
Study 39443081 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg twice daily for 8 weeks
Number of subjects: 80
Study 39443081 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 39443151 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D pCASL with TSE-CASPR
Number of subjects: 41
Study 39443151 — intervention group
Group type: COMPARATOR
Intervention: 3D pCASL with GRASE
Number of subjects: 41
Study 39443386 — intervention group
Group type: EXPERIMENTAL
Intervention: FAPI-PET/CT
Number of subjects: 232
Study 39443386 — intervention group
Group type: COMPARATOR
Intervention: Prospective observational trial (NCT04571086)
Number of subjects: 232
Study 39443386 — intervention group
Group type: COMPARATOR
Intervention: Retrospective analysis
Number of subjects: 232
Study 39443403 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole as primary therapy
Number of subjects: 218
Study 39443403 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole as salvage therapy
Number of subjects: 218
Study 39443403 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 218
Study 39443446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS)
Number of subjects: 140
Study 39443446 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 140
Study 39443463 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training (CT)
Number of subjects: 60
Study 39443527 — intervention group
Group type: COMPARATOR
Intervention: LPVr (400 mg/100 mg twice daily)
Number of subjects: 294
Study 39443527 — intervention group
Group type: EXPERIMENTAL
Intervention: LPVr + TLM (10 mg once daily)
Number of subjects: 294
Study 39443527 — intervention group
Group type: EXPERIMENTAL
Intervention: LPVr + ATV (20 mg once daily)
Number of subjects: 294
Study 39443527 — intervention group
Group type: COMPARATOR
Intervention: LPVr
Number of subjects: 294
Study 39443527 — intervention group
Group type: EXPERIMENTAL
Intervention: LPVr + TLM
Number of subjects: 294
Study 39443527 — intervention group
Group type: EXPERIMENTAL
Intervention: LPVr + ATV
Number of subjects: 294
Study 39443659 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (therapeutic doses)
Number of subjects: 0
Study 39443659 — intervention group
Group type: COMPARATOR
Intervention: No amiodarone (ineffective group)
Number of subjects: 0
Study 39443721 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the acute phase (8 times daily for up to 10 days)
Number of subjects: 155
Study 39443721 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the tapering phase (2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks)
Number of subjects: 155
Study 39443721 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the relapse prevention phase (scheduled based on symptom re-emergence for up to 6 months)
Number of subjects: 155
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized neurological examination
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (age ≥ 5 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional measurements
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory assessments (spirometry, maximal inspiratory and expiratory pressure, sniff nasal inspiratory pressure; age ≥ 5 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA-scan; age ≥ 2 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray of the left hand (age ≤ 17 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity MRI (age ≥ 10 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry for 8 days (age ≥ 2 years)
Number of subjects: 0
Study 39443859 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires (patient report and/or parent proxy; age ≥ 2 years)
Number of subjects: 0
Study 39443873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and nutrition intervention
Number of subjects: 94
Study 39443873 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study 39443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Shock Index (SI) ≥ 0.9
Number of subjects: 335
Study 39443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic sensory block height > 4
Number of subjects: 335
Study 39443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 335
Study 39443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Index alone
Number of subjects: 335
Study 39443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 335
Study 39443891 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 0
Study 39443891 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0
Study 39443891 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in New York metropolitan area
Number of subjects: 0
Study 39443924 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus sealer with sonic activation
Number of subjects: 72
Study 39443924 — intervention group
Group type: COMPARATOR
Intervention: AH Plus sealer without sonic activation
Number of subjects: 72
Study 39443924 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosequence BC sealer with sonic activation
Number of subjects: 72
Study 39443924 — intervention group
Group type: COMPARATOR
Intervention: Endosequence BC sealer without sonic activation
Number of subjects: 72
Study 39443924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic activation
Number of subjects: 72
Study 39443924 — intervention group
Group type: COMPARATOR
Intervention: Non-activation
Number of subjects: 72
Study 39443927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (0.3 mL)
Number of subjects: 20
Study 39443927 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine HCl 10 mg/mL (0.3 mL)
Number of subjects: 20
Study 39443927 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% and Papaverine HCl
Number of subjects: 20